YZC [YANZHOU COAL MINING CO] 6-K: Yanzhou Coal Mining Company Limited Date January 5,
[Yanzhou Coal Mining Company Limited Date January 5, 2016 By Zhang Baocai]
GSI [GENERAL STEEL] 8-K: General Steel Receives NYSE Notification Regarding Closing Price
[General Steel Receives NYSE Notification Regarding Closing Price Requirement Under NYSE's Continued Listing Standard In a notification letter dated January 4, 2016, the NYSE notified the Company that as of December 30, 2015, the average closing price of the Company over a consecutive 30-day trading period of $0.97. Under the NYSE regulations, the Company has a cure period of six] [General Steel to Divest Steel Manufacturing Business BEIJING, Jan. 5, 2016 /PRNewswire/ -- General Steel Holdings, Inc. ("General Steel" or the "Company") (NYSE: GSI), announced today that on December 30, 2015, the Company signed a series of restructuring agreements to effect the sale of its steel manufacturing business. Due to persistently depressed market trends for the steel business in China,] []
ZNH [CHINA SOUTHERN AIRLINES CO] 6-K: (Original Filing)
[CONTINUING CONNECTED TRANSACTIONS In order to comply with the various requirements under Chapter 14A of the Listing Rules in respect of continuing connected transactions of the Company, on 30 December 2015, the Company and certain subsidiaries of CSAHC have renewed the Media Service Framework Agreement and the Catering Services Framework Agreement, both for a term of three years commencing from] []
ZNH [CHINA SOUTHERN AIRLINES CO] 6-K: CONTINUING CONNECTED TRANSACTIONS In order to comply with
[CONTINUING CONNECTED TRANSACTIONS In order to comply with the various requirements under Chapter 14A of the Listing Rules in respect of continuing connected transactions of the Company, on 30 December 2015, the Company and certain subsidiaries of CSAHC have renewed the Media Service Framework Agreement and the Catering Services Framework Agreement, both for a term of three years commencing from] []
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate BEIJING, December 10, 2015 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on its Sabin Inactivated Polio Vaccine (or “sIPV”) candidate. In preparation of beginning human clinical trials, Sinovac is currently finalizing the clinical] [Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine BEIJING, January 4, 2016--Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the China Food and Drug Administration (CFDA) issued the new drug certificate and production license for its Enterovirus 71 ("EV71") vaccine. As previously announced, the CFDA completed its Good Manufacturing Practices] [FORM 6-K -------------- ---------- SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F ___ SINOVAC BIOTECH LTD. 6-K 1 v428191_6k.htm FORM 6-K]
CYD [CHINA YUCHAI INTERNATIONAL] 6-K: (Original Filing)
[CHINA YUCHAI ANNOUNCES BOARD CHANGE Singapore, Singapore, January 5, 2016 China Yuchai International Limited (NYSE: CYD) Weng Ming Hoh, President of China Yuchai, commented, We thank Meng Choong for his contributions during his tenure as a director and we wish him all the best in his future endeavours. About China Yuchai International http://www.cyilimited.com China Yuchai International Limited, through its] [FORM 6-K January 5, 2016 China Yuchai International Limited 16 Raffles Quay #26-00 x x n/a China Yuchai International Limited Weng Ming Hoh President/Director Description 99.1 Press Release dated January 5, 2016 - China Yuchai Annouces Board Change 6-K 1 htm_9943.htm LIVE FILING]
SVA [SINOVAC BIOTECH] 6-K: Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate
[Sinovac Obtains Clinical Trial Approval for Sabin-IPV Candidate BEIJING, December 10, 2015 -- Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the Company has obtained approval to begin human clinical trials on its Sabin Inactivated Polio Vaccine (or “sIPV”) candidate. In preparation of beginning human clinical trials, Sinovac is currently finalizing the clinical] [Sinovac Obtains New Drug Certificate and Production License for EV71 Vaccine BEIJING, January 4, 2016--Sinovac Biotech Ltd. (NASDAQ:SVA), a leading provider of biopharmaceutical products in China, today announced that the China Food and Drug Administration (CFDA) issued the new drug certificate and production license for its Enterovirus 71 ("EV71") vaccine. As previously announced, the CFDA completed its Good Manufacturing Practices] [FORM 6-K -------------- ---------- SINOVAC BIOTECH LTD. No. 39 Shangdi Xi Road Haidian District Beijing 100085, People’s Republic of China X Form 20-F ___ SINOVAC BIOTECH LTD. 6-K 1 v428191_6k.htm FORM 6-K]
CYD [CHINA YUCHAI INTERNATIONAL] 6-K: CHINA YUCHAI ANNOUNCES BOARD CHANGE Singapore, Singapore, January
[CHINA YUCHAI ANNOUNCES BOARD CHANGE Singapore, Singapore, January 5, 2016 China Yuchai International Limited (NYSE: CYD) Weng Ming Hoh, President of China Yuchai, commented, We thank Meng Choong for his contributions during his tenure as a director and we wish him all the best in his future endeavours. About China Yuchai International http://www.cyilimited.com China Yuchai International Limited, through its] [FORM 6-K January 5, 2016 China Yuchai International Limited 16 Raffles Quay #26-00 x x n/a China Yuchai International Limited Weng Ming Hoh President/Director Description 99.1 Press Release dated January 5, 2016 - China Yuchai Annouces Board Change 6-K 1 htm_9943.htm LIVE FILING]
